Key Financials Snapshot

TTM · Consolidated · ₹ in Cr
Market Cap
₹14708 Cr.
Stock P/E
85
P/B
14.6
Current Price
₹1428
Book Value
₹ 97.8
Face Value
1
52W High
₹1592
52W Low
₹ 847.9
Dividend Yield
0.14%

Vijaya Diagnostic Overview

Business

Vijaya Diagnostic Centre Ltd. is an integrated diagnostic chain primarily operating in South India, with a strong presence in Telangana and Andhra Pradesh. The company offers a comprehensive range of diagnostic services including pathology and radiology tests. Its core business model involves providing these services to individual patients, corporate clients, and through physician referrals, operating through a network of diagnostic centres and collection points. The company generates revenue by charging fees for a wide array of diagnostic tests, health check-up packages, and related services.

Revenue Mix

The company's revenue is primarily derived from two main segments:

Pathology Services: This includes a broad spectrum of blood, urine, and other bodily fluid tests for disease diagnosis, monitoring, and prevention.

Radiology Services: This segment encompasses imaging services such as X-rays, MRI, CT scans, Ultrasound, PET CT scans, and other advanced imaging techniques.

As an integrated player, both segments contribute significantly to its overall revenue.

Industry

Vijaya Diagnostic Centre operates in the rapidly growing Indian diagnostic services market, which is characterized by increasing health awareness, rising non-communicable diseases, and a shift towards preventive healthcare. The industry is highly fragmented with a mix of large national chains, regional players, hospital-based labs, and numerous unorganized local labs. Vijaya is positioned as a leading regional integrated diagnostic chain, particularly dominant in its home markets of Telangana and Andhra Pradesh. It differentiates itself through a comprehensive test menu, advanced equipment, and a widespread network within its operating regions, standing as a significant regional competitor against larger national diagnostic chains and smaller local players.

MOAT

Brand Reputation & Trust: An established and trusted brand name built over decades, particularly strong in its core markets of Hyderabad and other parts of South India. This drives patient preference and doctor referrals.

Extensive Network & Scale: A widespread network of diagnostic centres and collection points in its regions provides convenience and allows for economies of scale in operations, logistics, and procurement.

Integrated Model: Offering both pathology and radiology services under one roof provides a "one-stop shop" convenience for patients and referring physicians, enhancing customer stickiness.

Operational Efficiency: Over time, the company has developed processes and systems that contribute to efficient sample collection, processing, and reporting.

Growth Drivers

Increasing Healthcare Expenditure: Rising disposable incomes and greater health consciousness among the Indian population are driving higher spending on healthcare, including diagnostics.

Growing Burden of Chronic Diseases: The increasing prevalence of lifestyle diseases and chronic conditions necessitates regular diagnostic testing for early detection and disease management.

Preventive Healthcare Trend: A rising awareness and adoption of regular health check-ups and preventive screenings are boosting demand for diagnostic services.

Geographic Expansion: Opportunities to expand its network within its existing strong markets and into new Tier 2/3 cities within South India.

Technology Upgrades & New Tests: Continuous investment in advanced diagnostic equipment and introduction of specialized, high-end tests can drive higher value realization.

Risks

Intense Competition & Price Wars: The diagnostic market is highly competitive, leading to pricing pressures and potential margin erosion from national and regional players.

Regulatory Changes: Potential for government intervention in pricing diagnostic tests, changes in accreditation norms, or other healthcare regulations could impact profitability.

Dependence on Doctor Referrals: A significant portion of revenue is driven by referrals from doctors, making the company susceptible to changes in referral patterns or increased competition for physician engagement.

Technological Obsolescence: The need for continuous capital expenditure to upgrade equipment and adopt new technologies to remain competitive can be significant.

Talent Scarcity: Shortage of skilled pathologists, radiologists, and technicians can lead to higher manpower costs and operational challenges.

Quality Control: Any lapse in diagnostic accuracy or quality can severely damage reputation and customer trust.

Management & Ownership

Vijaya Diagnostic Centre was founded by Dr. S. Surendranath Reddy, who serves as the promoter. The management team is generally perceived as having deep domain expertise in the diagnostic industry, with a focus on operational efficiency and regional market penetration. The promoter group holds a significant stake in the company, aligning their interests with long-term growth. The company also has institutional and public shareholding following its IPO.

Outlook

Vijaya Diagnostic Centre is well-positioned to capitalize on the secular growth trends in the Indian diagnostic market, driven by its strong brand recall, integrated service model, and extensive network in its core South Indian markets. Its focus on a comprehensive test menu and operational efficiency provides a competitive edge. However, the company faces significant challenges from intense competition, particularly from larger national chains and rapidly expanding regional players, which can exert pressure on pricing and margins. Potential regulatory interventions on test pricing also remain a key risk. While its established regional leadership and integrated offering provide a stable base, sustained growth will depend on its ability to execute its expansion strategies effectively, maintain service quality, and navigate the competitive landscape without compromising profitability.

Vijaya Diagnostic Share Price

Live · BSE / NSE · Inception: 2002
₹ | |
Volume
Price

Key Financials — Profit & Loss

₹ in Cr · Consolidated · annual

Vijaya Diagnostic Quarterly Results

#(Fig in Cr.) Mar 2024 Jun 2024 Sep 2024 Dec 2024 Mar 2025 Jun 2025 Sep 2025 Dec 2025 Mar 2026 Jun 2026
Net Sales 155 156 183 169 173 188 202 205 219 231
Other Income 3 4 5 5 6 7 6 5 2 9
Total Income 158 160 187 174 179 195 208 210 222 240
Total Expenditure 92 95 107 102 104 115 120 119 124 132
Operating Profit 66 65 80 72 74 81 88 91 98 107
Interest 6 6 6 7 7 7 8 9 9 11
Depreciation 16 17 17 18 19 21 22 24 24 25
Exceptional Income / Expenses 0 0 0 0 -1 0 0 0 0 0
Profit Before Tax 44 42 57 47 47 52 58 58 64 71
Provision for Tax 10 10 15 11 13 14 15 15 16 18
Profit After Tax 34 32 42 35 35 39 43 43 48 53
Adjustments -0 -0 -0 0 0 0 -0 -0 0 -0
Profit After Adjustments 33 31 42 35 35 39 43 43 48 53
Adjusted Earnings Per Share 3.3 3.1 4.1 3.4 3.4 3.8 4.2 4.2 4.7 5.2

Vijaya Diagnostic Profit & Loss

#(Fig in Cr.) Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026 TTM
Net Sales 293 339 377 462 459 548 681 814 857
Other Income 10 15 12 13 14 24 18 21 22
Total Income 303 354 389 475 473 572 700 835 880
Total Expenditure 184 206 211 259 277 330 408 477 495
Operating Profit 118 148 178 217 196 242 292 358 384
Interest 14 15 15 16 21 24 27 33 37
Depreciation 40 49 50 53 62 57 71 92 95
Exceptional Income / Expenses 0 0 0 0 0 -2 -1 0 0
Profit Before Tax 65 83 112 147 114 159 193 233 251
Provision for Tax 19 21 27 37 28 39 49 60 64
Profit After Tax 46 63 85 111 85 120 144 173 187
Adjustments -0 0 -1 -1 -1 -1 0 0 0
Profit After Adjustments 46 63 84 110 85 119 144 173 187
Adjusted Earnings Per Share 4.5 6.1 8.3 10.8 8.3 11.6 14 16.8 18.3

Vijaya Diagnostic Balance Sheet

#(Fig in Cr.) Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026
Shareholder's Funds 207 275 359 468 545 657 799 957
Minority's Interest -0 -0 0 1 2 3 0 0
Borrowings 32 22 3 0 0 0 0 0
Other Non-Current Liabilities 110 126 128 169 232 247 312 426
Total Current Liabilities 57 59 44 66 66 73 163 124
Total Liabilities 405 481 535 705 845 980 1274 1507
Fixed Assets 259 272 268 370 524 742 865 1069
Other Non-Current Assets 9 23 28 64 46 26 102 116
Total Current Assets 137 186 239 270 276 211 307 322
Total Assets 405 481 535 705 845 980 1274 1507

Vijaya Diagnostic Cash Flow

#(Fig in Cr.) Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026
Opening Cash & Cash Equivalents 16 10 56 7 11 24 22 13
Cash Flow from Operating Activities 91 106 130 158 165 183 224 271
Cash Flow from Investing Activities -90 -31 -130 -123 -110 -142 -182 -174
Cash Flow from Financing Activities -7 -30 -49 -31 -42 -45 -52 -69
Net Cash Inflow / Outflow -6 46 -49 4 13 -4 -9 27
Closing Cash & Cash Equivalent 10 56 7 11 24 22 13 40

Vijaya Diagnostic Ratios

# Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026
Earnings Per Share (Rs) 4.5 6.13 8.28 10.76 8.29 11.61 14.01 16.81
CEPS(Rs) 8.43 10.95 13.3 16.02 14.39 17.26 20.89 25.73
DPS(Rs) 0 0 0 1 1 1 2 2
Book NAV/Share(Rs) 20.11 26.92 35.13 45.73 53.18 64.09 76.29 92.73
Core EBITDA Margin(%) 36.95 39.14 44.05 44.05 39.64 39.74 40.1 41.38
EBIT Margin(%) 26.95 29.16 33.81 35.43 29.28 33.35 32.27 32.66
Pre Tax Margin(%) 22.32 24.62 29.76 31.88 24.72 28.97 28.35 28.58
PAT Margin (%) 15.81 18.45 22.6 23.93 18.55 21.84 21.1 21.24
Cash Profit Margin (%) 29.36 32.96 35.99 35.33 31.99 32.24 31.46 32.52
ROA(%) 11.42 14.11 16.76 17.85 11 13.11 12.76 12.44
ROE(%) 22.58 26.07 26.91 26.85 16.89 19.96 19.99 19.91
ROCE(%) 31.56 35.47 37.97 39.37 26.53 30.4 30.2 30.28
Receivable days 11.38 9.22 7.12 6.5 7.65 8.57 8.3 7.98
Inventory Days 2.72 2.67 2.62 2.73 2.51 2.41 2.71 2.2
Payable days 196.16 180.59 140.18 111.8 152.97 169.19 142.28 136.27
PER(x) 0 0 0 40.7 47.18 54.69 71.86 51.24
Price/Book(x) 0 0 0 9.57 7.36 9.91 13.2 9.29
Dividend Yield(%) 0 0 0 0.23 0.26 0.16 0.2 0.23
EV/Net Sales(x) -0.01 -0.24 -0.49 9.24 8.44 11.73 15.09 10.82
EV/Core EBITDA(x) -0.03 -0.55 -1.04 19.73 19.76 26.58 35.28 24.63
Net Sales Growth(%) 0 15.8 11.19 22.73 -0.68 19.29 24.39 19.49
EBIT Growth(%) 0 25.31 28.9 28.63 -17.93 35.86 20.39 20.92
PAT Growth(%) 0 35.09 36.19 30 -23.01 40.41 20.19 20.3
EPS Growth(%) 0 36.23 35.09 29.84 -22.92 40.03 20.67 19.99
Debt/Equity(x) 0.2 0.12 0.01 0 0 0 0 0
Current Ratio(x) 2.41 3.18 5.4 4.08 4.17 2.9 1.89 2.6
Quick Ratio(x) 2.37 3.13 5.34 4.02 4.14 2.83 1.86 2.56
Interest Cover(x) 5.83 6.42 8.35 9.96 6.42 7.61 8.22 8
Total Debt/Mcap(x) 0 0 0 0 0 0 0 0

Growth Rates

Compounded annual
# 1 Year 3 Year 5 Year 10 Year
Sales CAGR +20% +21% +17% —
Operating Profit CAGR +23% +22% +15% —
PAT CAGR +20% +27% +15% —
Share Price CAGR +42% +41% +21% —
ROE Average +20% +20% +21% +22%
ROCE Average +30% +30% +31% +33%

Vijaya Diagnostic Shareholding Pattern

Latest · Jun 2026
100% held
Promoters 52.51 %
FII 11.66 %
DII (MF + Insurance) 31.6 %
Public (retail) 4.23 %
# Mar 2024 Jun 2024 Sep 2024 Dec 2024 Mar 2025 Jun 2025 Sep 2025 Dec 2025 Mar 2026 Jun 2026
Promoter 54.0653.9353.9153.9153.0552.6352.652.652.5152.51
FII 20.0920.0818.1417.5419.3619.5618.2715.113.3811.66
DII 20.821.4923.4624.6323.7224.0725.3428.5929.9331.6
Public 5.054.54.493.923.873.743.793.714.184.23
Others 0000000000
Total 100100100100100100100100100100

Vijaya Diagnostic Peer Comparison

Hospital & Healthcare Services Edit Columns

Vijaya Diagnostic Quarterly Price

10-year quarterly close · BSE
Show Value Show %

News & Updates

See more…

Vijaya Diagnostic Pros & Cons

Pros

  • Debtor days have improved from 142.28 to 136.27days.
  • Company is almost debt free.

Cons

  • Stock is trading at 14.6 times its book value.
Want to Start Investing in Top Unlisted Stocks?

Our experts help you choose the right stocks based on performance, risk, and growth potential.

whatsapp